Atif Zaman

Indian Institute of Information Technology Design and Manufacturing Jabalpur

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

William M. Lee

The University of Texas Southwestern Medical Center

Santiago J. Muñoz

Johns Hopkins University

Robert J. Fontana

University of Michigan–Ann Arbor

Brendan M. McGuire

University of Alabama at Birmingham

Natalie Murray

University of Pittsburgh

Lorenzo Rossaro

Gilead Sciences (United States)

Timothy M. McCashland

University of Nebraska Medical Center

Hugo R. Rosen

University of Colorado Denver

Adrian Reuben

King's College London

K. Rajender Reddy

University of Pennsylvania

Cooperative Institutions

Advanced Systems Technology (United States)

131

Oregon Health & Science University

104

Harvard University

University of California, San Francisco

University of Washington

University of Pittsburgh

Mayo Clinic

The University of Texas Southwestern Medical Center

University of Pennsylvania

University of Michigan–Ann Arbor

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Stopping Lamivudine Therapy in Hepatitis B–Infected Patients

Journal watch (2009)

Atif Zaman

Can hepatitis B e antigen (HBeAg)-positive patients receiving hepatitis B virus (HBV) treatment reasonably stop such treatment if they seroconvert to

Rescue therapy

Hepatitis B

10.1056/jg200909180000004

Cite

Citations (0)

A Global View of HCV Infection and Barriers to Treatment

Journal watch (2013)

Atif Zaman

As we anticipate a new generation of treatments for hepatitis C virus (HCV) infection, it is important to view the global picture of HCV infection. The

10.1056/jg201305100000004

Cite

Citations (0)

Thiazolidinediones for the Treatment of Nonalcoholic Steatohepatitis

Journal watch (2009)

Atif Zaman

Nonalcoholic steatohepatitis (NASH) is a common chronic liver disorder that can progress to cirrhosis, liver failure, and hepatocellular carcinoma.

Nonalcoholic steatohepatitis

Pioglitazone

Steatohepatitis

10.1056/jg200902270000004

Cite

Citations (0)

Acute Idiosyncratic Drug-Induced Injury Can Lead to Chronic Liver Disease

Journal watch (2007)

Atif Zaman

Drug-induced liver injury (DILI) is an important problem, especially with recent increases in use of herbal remedies and dietary supplements.

Chronic liver disease

10.1056/jg200703300000004

Cite

Citations (0)

Racial Disparities in Idiosyncratic Drug-Induced Liver Injury

Journal watch (2017)

Atif Zaman

Over the last several years, research from large prospective cohort studies, such as the current one from the Drug-Induced Liver Injury (DILI) Network,

10.1056/nejm-jw.na44748

Cite

Citations (0)

Maintenance Interferon Therapy for Patients with Chronic Hepatitis C Infections

Journal watch (2007)

Atif Zaman

Fifty to sixty percent of patients infected with hepatitis C virus (HCV) have treatment success with pegylated interferon plus ribavirin. Low-dose interferon without ribavirin is currently being evaluated as maintenance therapy for suppressing viral replication and retarding liver-fibrosis progression to prevent complications of advanced liver disease and to lengthen survival. In this randomized trial, investigators assessed the ability of interferon alfa-2a to lengthen complication-free survival in HCV-positive patients with compensated cirrhosis. From …

Pegylated interferon

Hepatitis C

Liver disease

10.1056/jg200707270000002

Cite

Citations (0)

Eltrombopag for Thrombocytopenia in Cirrhotic Patients with HCV

Journal watch (2007)

Atif Zaman

Cirrhotic patients who are infected with hepatitis C virus (HCV) often experience thrombocytopenia as a result of the combination of portal

Eltrombopag

10.1056/jg200711280000001

Cite

Citations (0)

Sofosbuvir plus Velpatasvir for Chronic Pangenotypic HCV Infection: Phase III Results

Journal watch (2015)

Atif Zaman

An experimental, once-daily pill for hepatitis C virus (HCV) leads to high rates of sustained virologic response across a wide range of patients, according to findings from four international, industry-supported, phase III trials reported below. The pill combines sofosbuvir (400 mg) with velpatasvir (100 mg; a novel pan-genotypic HCV NS5A inhibitor). The primary endpoint in all studies was sustained virologic response at 12 weeks after treatment ended (SVR12). Some 700 patients with HCV genotypes 1, 2, 4, and 6 were randomized to receive sofosbuvir–velpatasvir or placebo for 12 weeks; …

Pill

Sofosbuvir

Clinical endpoint

Hepatitis C

10.1056/nejm-jw.na39643

Cite

Citations (0)

Gut Dysbiosis May Play a Role in Nonalcoholic Fatty Liver Disease

Journal watch (2016)

Atif Zaman

Gut dysbiosis — a microbial imbalance implicated in obesity, cardiovascular disease, and metabolic syndrome — has recently been suggested in animal

Dysbiosis